INCYTE CORPORATION (INCY) — financial distillation
Annual history (10-K)
Quarterly history (10-Q)
Two headline lines are shown to start. Click any item in a legend to add or remove it — every figure on the chart is one the table below also carries, for the period it names.
In brief, from the full filed history
- Revenue grew from $9.3M (period ending 2009-12-31) to $5.14B (period ending 2025-12-31) — a 48.4% annual pace across 16 year(s) of filed history.
- Net margin expanded from 9.4% to 25.0% over that same span.
- Across 49 tracked quarters, the strongest was $1.37B (quarter ending 2025-09-30) and the weakest was $16.8M (quarter ending 2011-09-30).
Annual — most recent 10-K
| Line | Value | Period ends | Form | Filing |
|---|---|---|---|---|
| Revenue | $5.14B | 2025-12-31 | 10-K | 0000879169-26-000010 |
| Operating income | $1.51B | 2025-12-31 | 10-K | 0000879169-26-000010 |
| Net income | $1.29B | 2025-12-31 | 10-K | 0000879169-26-000010 |
| Diluted EPS | $6.41 | 2025-12-31 | 10-K | 0000879169-26-000010 |
| Total assets | $6.96B | 2025-12-31 | 10-K | 0000879169-26-000010 |
| Total liabilities | $1.79B | 2025-12-31 | 10-K | 0000879169-26-000010 |
| Cash & equivalents | $3.10B | 2025-12-31 | 10-K | 0000879169-26-000010 |
| Operating cash flow | $1.41B | 2025-12-31 | 10-K | 0000879169-26-000010 |
Quarterly — most recent 10-Q
| Line | Value | Period ends | Form | Filing |
|---|---|---|---|---|
| Revenue | $1.27B | 2026-03-31 | 10-Q | 0000879169-26-000026 |
| Operating income | $301.1M | 2026-03-31 | 10-Q | 0000879169-26-000026 |
| Net income | $303.3M | 2026-03-31 | 10-Q | 0000879169-26-000026 |
| Diluted EPS | $1.47 | 2026-03-31 | 10-Q | 0000879169-26-000026 |
| Total assets | $7.34B | 2026-03-31 | 10-Q | 0000879169-26-000026 |
| Total liabilities | $1.72B | 2026-03-31 | 10-Q | 0000879169-26-000026 |
| Cash & equivalents | $3.46B | 2026-03-31 | 10-Q | 0000879169-26-000026 |
| Operating cash flow | $369.4M | 2026-03-31 | 10-Q | 0000879169-26-000026 |
Reading
The figures above are taken directly from filings with the U.S. Securities and Exchange Commission. The reading below was generated by a local language model from only those figures; it introduces no numbers of its own. It is not investment advice.
Incyte Corporation’s business scale is substantial, with a revenue of $5.14 billion in the most recent annual period, marking a significant increase from its modest beginnings of $9.3 million in 2009. The company’s revenue growth trajectory has been robust, averaging a 48.4% annual pace over the past 16 years, as evidenced by the pre-computed trend fact. This consistent expansion underscores Incyte’s successful market penetration and product development in its pharmaceutical sector.
The company’s financial performance has also shown resilience, with net income reaching $1.29 billion in 2025, following a trough of negative $295.7 million in 2020. This period included a notable recovery, with net income surging to $948.6 million in 2021 and further increasing to $340.7 million in 2022. The net margin has expanded from 9.4% to 25.0% over the same period, indicating improved profitability and operational efficiency.
Incyte’s financial health remains strong, with cash and equivalents standing at $3.10 billion at year-end 2025 and increasing to $3.46 billion by the most recent quarterly filing. Operating cash flow has also been consistently positive, reaching $1.41 billion in the annual period ending 2025-12-31 and further growing to $369.4 million in the latest quarter. Investors should monitor Incyte’s ability to sustain this growth and profitability amidst potential market challenges, as well as its ongoing product development efforts and regulatory approvals.
Source: SEC EDGAR company facts for CIK 0000879169 · filings index